New Study Reveals Pradaxa Benefits Overshadowed by Deadly Bleeding Side Effects
By Andrea Gressman
New Pradaxa studies are raising more concerns about the dangers of internal bleeding, a well-known side effect of Pradaxa. These concerns are also coming in the wake of mounting Pradaxa lawsuits.
There is already a great deal of concern regarding potentially fatal internal bleeding brought about by Pradaxa. However, additional studies are adding fuel to the already raging fire when it comes to Pradaxa lawsuits. The Archives of Internal Medicine contains the study, which found that the seriousness of Pradaxa bleeding side effects totally cancels out any benefits the drug may otherwise offer to Acute Coronary Syndrome sufferers.
The study drives home the reality of the severity of the bleeding side effects caused by Pradaxa, along with the potentially deadly fact that no cure exists to treat the severe and uncontrollable bleeding side effects Pradaxa brings about.
The study by the Archives of Internal Medicine reviewed information on 30,000 ACS patients, 50% of whom used Pradaxa, or an alternate blood thinner medication, as a treatment, while the remainder took placebos. The study indicated that using Pradaxa or a new blood thinner tripled the risk of dangerous internal bleeding. However, stent thrombosis reduction or problems associated with the heart proved minimal at best. Very little improvement in survival of patients who received drug treatment was noted.
Pradaxa Lawsuits Pertaining to Internal Bleeding Side Effects
To lower the probability of a stroke occurring in patients suffering from fibrillation, Pradaxa’s application for approval was accepted by the FDA in October 2010. The drug’s design was meant to add convenience over warfarin, which had been available for a while.
Serious internal bleeding may result from warfarin as well as Pradaxa. However, with warfarin, a dose of vitamin K will immediately put a stop to the bleeding. Unfortunately, there is no such luck with Pradaxa. Internal bleeding caused by this drug has no known treatment. Even though Pradaxa may be effectively removed from the bloodstream via dialysis, the journal Neurology discovered the treatment carries high risks and may take too long to effectively halt internal bleeding caused by Pradaxa. Subsequently, there has been a flood of Pradaxa lawsuits filed and it doesn’t look like that is going to slow down anytime soon.
The FDA issued a communication regarding drug safety in December of 2010 indicating report reviews regarding serious bleeding caused by Pradaxa. The FDA, by the end of the year, had received over 500 reported fatalities in the United States, all resulting from Pradaxa use.
In Illinois, Southern District, U.S. Court, Pradaxa lawsuits pertaining to the internal bleeding, which are federally-filed, are being consolidated in a MDL. Along with other allegations, these Pradaxa lawsuits claim that Boehringer Ingelheim Pharmaceuticals, Inc., who manufactures Pradaxa, failed to give proper and adequate warnings to physicians who prescribe the drug of the dangers linked to the drug.
It is probable that those victimized by the Pradaxa side effects are eligible for compensatory damages to help offset medical expenses, lost salary, physical agony, and more. For more information regarding the filing of a Pradaxa lawsuit visit the Pradaxa Internal Bleeding Class Action Lawsuit Investigation page to consult with one of our experienced and knowledgeable Pradaxa lawyers.
Updated October 18th, 2012
All medical device, dangerous drug and medical class action and lawsuit news updates are listed in the Drug and Medical Device section of Top Class Actions.
Top Class Actions Legal Statement
